Chemical formula: C₁₃H₁₇N Molecular mass: 187.286 g/mol PubChem compound: 26757
Selegiline is a selective MAO-B-inhibitor which prevents dopamine breakdown in the brain. It also inhibits the reuptake of dopamine at the presynaptic dopamine receptor. These effects potentiate dopaminergic function in the brain and help to even out and prolong the effect of exogenous and endogenous dopamine. Thus, selegiline potentiates and prolongs the effect of levodopa in the treatment of parkinsonism.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N04BD01 | Selegiline | N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BD Monoamine oxidase B inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ELDEPRYL Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Selegiline is an active ingredient of these brands:
Australia (AU)
Finland (FI)
France (FR)
Ireland (IE)
Israel (IL)
Malta (MT)
Mexico (MX)
Romania (RO)Singapore (SG)Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
